Objectives: Japan has one of the highest endemic rates of hepatitis C virus (HCV) infection. Treatments in Japan are currently limited to interferon-alfa-based regimens, which are associated with tolerability and efficacy issues. A novel regimen combining two oral HCV therapies, daclatasvir and asunaprevir (DCV þ ASV), has shown favorable results in Japanese patients with chronic genotype 1b HCV infection. Comparisons of clinical and economic outcomes associated with DCV þ ASV treatment and current standards of care were investigated. Methods: The MOdelling the NAtural histoRy and Cost-effectiveness of Hepatitis cost-effectiveness model projected outcomes in 1000 patients aged 70 years with either chronic hepatitis C or compensated cirrhosis over a lifetime simulation. Japanesespecific disease transition rates were used, and discounting was applied annually at a rate of 2%. Efficacy data for DCV þ ASV and telaprevir triple therapy (telaprevir þ pegylated interferon-alfa þ ribavirin [TVR þ pegIFN-α/RBV]) were obtained from a Japanese subgroup analysis found within a global meta-analysis: sustained virological response rates of 74%, 85%, and 87% were reported for null responders (NRs), partial responders (PRs), and interferon-alfa-ineligible/intolerant patients, respectively, treated with DCV þ ASV, and rates of 42% and 59% were reported for NRs and PRs, respectively, treated with TVR þ pegIFN-α/RBV. Results: Initiating DCV þ ASV treatment in patients in the chronic hepatitis C disease stage resulted in quality-adjusted life-year gains of 0.96 and 0.77 over TVR þ pegIFN-α/RBV for NRs and PRs, respectively, and a gain of 2.61 in interferonalfa-ineligible/intolerant patients over no treatment. Similarly, quality-adjusted life-year gains of 1.11, 0.90, and 3.05 were observed when initiating treatment in patients in the compensated cirrhosis stage. Cumulative lifetime events of decompensated cirrhosis, hepatocellular carcinoma, and liver-related mortality were reduced by up to 66, 115, and 128, respectively, with DCV þ ASV treatment. Conclusions: There is a lack of successful therapies for patients with HCV who have previously failed to achieve sustained virological response or are ineligible for interferon-alfa-based therapies. Results demonstrate that the provision of an alternative, interferon-alfa-free regimen, such as DCV þ ASV, offers significant value in terms of avoiding life-threatening liver complications and increasing patients' quality of life.
Introduction
The global burden of the hepatitis C virus (HCV) is significant, with an estimated 3% of the world's population chronically infected [1] . Japan has one of the highest endemic rates of HCV infection; approximately 2 million people are infected, predominately with genotype 1b, resulting in more than 30,000 liverrelated deaths each year [2] [3] [4] . An interferon-alfa-based treatment regimen is the mainstay of therapy for HCV-infected individuals [5] , with the aim of eradicating the infection and thereby preventing disease progression. The recognized clinical end point for HCV eradication is sustained virological response (SVR), and recent advances have given rise to SVR rates of the order of 70% in treatment-naive patients, using a triple therapy regimen consisting of pegylated interferon-alfa, ribavirin, and a protease inhibitor (e.g., telaprevir or boceprevir [6, 7] ). Interferonalfa-based regimens, however, are associated with tolerability issues; adverse events commonly observed include anemia, pyrexia, rash, renal toxicity, and gastrointestinal-related disorders [8, 9] , and there remains a proportion of patients who do not achieve SVR, particularly if they are previous nonresponders. For those patients intolerant of or ineligible for interferon-alfa-based therapy, there is currently no approved treatment option and they remain at risk of developing life-threatening complications including decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC).
An interferon-alfa-free, all-oral regimen comprising daclatasvir and asunaprevir has been investigated for the treatment of patients with HCV genotype 1b infection [10] . Both daclatasvir and asunaprevir have demonstrated robust antiviral activity, with no clinically meaningful pharmacokinetic interactions when coadministered [11] . This regimen presents a significant step forward in the treatment of HCV infection for both untreated patients and those intolerant of or ineligible for interferon-alfa-based regimens. Daclatasvir is a first-in-class NS5A replication complex inhibitor with potent pan-genotypic antiviral activity in vitro (HCV genotypes 1-6) [12] , and asunaprevir is a selective NS3 protease inhibitor with antiviral activity against HCV genotypes 1, 4, 5, and 6 in vitro [13] .
This study aimed to model the lifetime clinical and economic outcomes associated with the use of daclatasvir combined with asunaprevir (DCV þ ASV) for the treatment of patients with chronic HCV genotype 1b infection, specifically in a Japanese setting, who are either intolerant of or ineligible for interferonalfa-based therapies, and those who did not respond to previous interferon-alfa-based treatment. Comparisons against current treatment options were made: telaprevir combined with pegylated interferon-alfa and ribavirin (TVR þ pegIFN-α/RBV), pegylated interferon-alfa and ribavirin (pegIFN-α/RBV), and no treatment. Because of the relative lack of data associated with DCV þ ASV treatment, sensitivity analyses were performed using efficacy rates derived from a global meta-analysis, with the intention of gaining a broader perspective of how DCV þ ASV might perform in the clinical setting.
Methods

Model
The objective of this study was to compare the long-term clinical and economic outcomes of DCV þ ASV with the current standard of care for chronic HCV genotype 1b infection in Japan. A modeling analysis was performed to predict the lifetime clinical and economic outcomes associated with DCV þ ASV treatment using a previously published and validated computer cohort simulation model [14] . The model used (the MOdelling the NAtural histoRy and Cost-effectiveness of Hepatitis [MONARCH] model) is a cohort-based Markov lifetime simulation created in Microsoft Excel and designed to model the natural history of HCV and its complications [14] [15] [16] . The model runs in annual cycles over a variable time horizon, up to patient lifetime (80 years from start). Cohorts of 1000 patients are defined and enter the model at either the chronic hepatitis C (CHC) or the compensated cirrhosis (CC) disease stage. From here, those with CHC can progress to CC and all patients can progress to DC, HCC, death, or a state of SVR. The MONARCH model flow diagram is presented in Figure. 1. The model outputs total costs, incidence of clinical events, qualityadjusted life-years (QALYs), and life expectancy. Costs, QALYs, and life-years were all discounted at a rate of 2%, in line with current Japanese guidelines.
Disease transition rates are applied annually to the prevalent population in each health state to model the natural history of HCV. Patients who achieve SVR from the state of CHC remain in the state of SVR for the duration of the simulation, whereas those who achieve SVR from the state of CC may relapse and progress to HCC. In those subjects failing to respond to treatment, CHC progression continues from whichever disease stage they were in at initiation of antiviral therapy. All transition rates are drawn from recently published literature specific to the Japanese setting.
All-cause mortality is incorporated into the model via the use of Japanese-specific abridged life tables and affects patients in the CHC, CC, and SVR Markov states. The transition rates used in the model are presented in Table 1 .
Health states within the model are subject to specific cost and utility values, applied annually. CC, compensated cirrhosis; CHC, chronic hepatitis C; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; SE, standard error.
values are therefore specific to Japan and are illustrated in Table 2 . Therapy-specific efficacy data are applied to the cohort to determine the distribution of patients among CHC, CC, and SVR health states after treatment initiation. Each therapy uses a course of antiviral treatment. The duration of antiviral consumption differs depending on the drugs used and affects the adverseevent profile associated with each treatment. Efficacy data sources for this study are described below. It is assumed that all patients complete treatment.
The costs associated with adverse events are modeled as a perevent cost. Each patient who suffers an adverse event is assumed to incur a cost that relates to the duration of his or her respective treatment. Only rash and anemia are modeled; it is assumed that all other adverse events would either not incur an additional cost or would occur too infrequently to affect the results substantially. The weekly costs of rash and anemia used (¥2,634.08 and ¥2,135.63, respectively) were derived from the hepatologist survey and National Health Insurance costs, assuming an average duration of 24 weeks, the same duration as therapy with pegIFN-α/RBV.
Analysis Plan
Using Japanese-specific disease progression rates, the natural history of HCV infection in cohorts of 1000 patients aged 70 years was modeled; 50% of the cohort members were female. Patients were simulated until death, and the predicted clinical outcomes and costs were recorded. Results for DCV þ ASV were compared with simulations of treatment with TVR þ pegIFN-α/RBV, pegIFN-α/RBV, and no treatment to quantify the potential benefit of DCV þ ASV antiviral therapy. The base-case analysis incorporated the following: Null response was defined as a decrease in HCV RNA by at least 2 log by week 12 but detectable HCV RNA during the therapy period.
Partial response was defined as a reduction of 2 log or more from baseline in HCV RNA but never achieving undetectable HCV RNA after at least 12 weeks. Pegylated interferon-alfa-intolerant/ineligible patients include those who previously discontinued interferon-alfabased therapy because of an adverse reaction or have a contraindication, and are therefore naive to interferon-alfa-based therapy.
A sensitivity analysis using results from a global metaanalysis was undertaken to provide insight into the potential variation in treatment effects.
Data Sources and Assumptions
Base-case analysis
For the base-case analysis, Japanese-specific results were taken from a previously undertaken global meta-analysis, in which a subgroup analysis of Japan-only studies was incorporated [17, 18] . A recent phase 3 clinical trial for DCV þ ASV undertaken in Japanese patients with chronic HCV genotype 1b infection (AI447026, NCT01497834) was incorporated within the metaanalysis. Results from this trial were incorporated in the basecase analysis to provide an insight into the clinical effectiveness of DCV þ ASV in an interferon-alfa-ineligible and intolerant cohort, which was not part of the meta-analysis. Treatmentrelated effects are reported in Table 3 .
DCV þ ASV phase 3 clinical trial AI447026 included two parallel populations: prior nonresponder (null and partial responders; n ¼ 87) and interferon-alfa-intolerant/ineligible (n ¼ 135) [10] . All subjects were administered 60 mg of daclatasvir once daily and 100 mg of asunaprevir twice daily for 24 weeks and followed for 24 weeks after the last dose of study drug. The primary efficacy end point was the proportion of subjects with SVR 24 , defined as HCV RNA below the lower limit of quantitation (o15 IU/mL) target detected or not detected at follow-up week 24 for each population. Safety was assessed as a secondary end point.
Meta-analysis and Japanese-specific subgroup analysis
The meta-analysis was performed to determine the relative efficacy and safety of different HCV treatment regimens used worldwide [17, 18] . Trials investigating the treatment of adults with CHC, regardless of HCV genotype, who were either naive to treatment or had been previously treated with an interferon-alfabased therapy, were included. Relevant articles published in the year 2000 or later were identified through searches of the PubMed 
database. Randomized clinical trials of pegIFN-α/RBV and either single-arm or randomized clinical trials of TVR þ pegIFN-α/RBV were included. The primary efficacy outcome measure was SVR 24 weeks following the completion of treatment (SVR 24 ). A total of 58 studies were included in the meta-analysis; among these, five were conducted in Japan and included in the Japanese-specific subgroup analysis. The meta-analysis was performed with a Bayesian hierarchical model. The foundational treatment was set as pegIFN-α/RBV and, for each end point, the response rate of pegIFN-α/RBV was allowed to vary from study to study; however, the odds ratio between each pair of treatments was assumed to be constant across studies, conditional on covariates and treatment arms. Each study was assumed to be sampled from a larger population of studies. The log odds of response for pegIFN-α/RBV in study s was modeled as follows:
where P t,s is the probability of response for treatment t in study s. Study-level effects are modeled with a distribution of α s $ Nðμ α , τ The data are allowed to shape the amount of variability across studies and, because of the hyper priors carrying little prior information, the amount of heterogeneity between studies is also largely determined by the data. The log-odds of response to a treatment is as follows:
The θ's represent treatment effects. For pegIFN-α/RBV, the treatment effect is assumed to be 0, allowing α s to be identified as the pegIFN-α/RBV log-odds for study s, while the treatment effects for TVR þ pegIFN-α/RBV and DCV þ ASV are modeled independently with "flat" prior distributions N(0,10 2 ).
The following covariates (denoted by Z) were incorporated in the analysis of SVR 24 ). Posterior distributions for the terms in the model were computed and, on the basis of these, posterior mean odds ratios for response with DCV þ ASV therapy versus other therapies were calculated.
The Japanese-specific subgroup meta-analysis for SVR 24 modeled the effects of the covariates using all studies (58 studies globally) and all populations, as in the global meta-analysis, but the estimates of the efficacy of the therapies in Japanese patients uses only the Japanese trials (five trials conducted in Japan). This modeling creates common effects of the covariates, but completely separate effects for a treatment arm, depending on country (Japan vs. outside Japan). Of the five studies conducted in Japan, safety/tolerability end points were available from the extracted populations or treatment arms for only three of these studies. Because of sparse data, formal modeling of the safety and tolerability end points for the Japan subgroup was not performed; thus, although adverse-event rates applied in the model are therapy-specific, they remain constant across analyses.
Sensitivity analysis
Because data regarding the effectiveness of DCV þ ASV are relatively few, sensitivity analyses were undertaken around the base case to provide some insight into the potential effect on outcomes with varying efficacy. Patients with chronic HCV infection were modeled. Results from the full data set of the DCV þ ASV, daclatasvir þ asunaprevir; pegIFN-α/RBV, pegylated interferon-alfa þ ribavirin; SE, standard error; SVR, sustained virological response; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin. * Adverse-event data were taken directly from the data tables provided within the meta-analysis relating to the DCV þ ASV trial, and SVR rates were taken directly from the trial itself. † Combined with 24 wk of pegIFN-α/RBV.
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Table 4 -Results of base-case analysis for patients with chronic HCV (N ¼ 1,000) . CC, compensated cirrhosis; DC, decompensated cirrhosis; DCV þ ASV, daclatasvir þ asunaprevir; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LM, liver-related mortality; NA, not applicable; pegIFN-α/RBV, pegylated interferon-alfa þ ribavirin; SVR, sustained virological response; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin; QALY, qualityadjusted life-year. Notes: Costs and QALYs are presented on a per-patient level. Comparisons of cost differences and numbers needed to treat are made against appropriate comparators, for example, DCV þ ASV: Null responders are compared only with other null responder cohorts (or the no treatment cohort).
Table 5 -Results of base-case analysis for patients with compensated cirrhosis (N ¼ 1,000) . DC, decompensated cirrhosis; DCV þ ASV, daclatasvir þ asunaprevir; HCC, hepatocellular carcinoma; LM, liver-related mortality; NA, not applicable; pegIFN-α/RBV, pegylated interferon-alfa þ ribavirin; SVR, sustained virological response; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin; QALY, quality-adjusted life-year. Notes: Costs and QALYs are presented on a per-patient level. Comparisons of cost differences and numbers needed to treat are made against appropriate comparators, for example, DCV þ ASV: Null responders are compared only with other null responder cohorts (or the no treatment cohort).
global meta-analysis were used to provide additional insight into the effects of treatment among null and partial responders. Efficacy (SVR 24 ) and safety (rate of anemia and rash) data used in both the base-case and sensitivity analysis are included in Table 4 .
Model assumptions
1. If a patient achieves SVR from chronic HCV, he or she remains in a state of SVR and cannot progress to end-stage liver disease complications. 2. Liver transplant is not considered as a treatment option/ disease state because of it not being possible or appropriate for most patients in Japan [3] . 3. No patients discontinue therapy. 4. No therapy-related QALY decrements are applied to patients when receiving treatment because of a lack of consistent information. 5. Efficacy rates remain constant across CHC and CC disease stages. 6. Therapy costs are not modeled because of the costs of daclatasvir and asunaprevir not being published.
Results
Base Case
The base-case analysis suggested that DCV þ ASV is superior to TVR þ pegIFN-α/RBV, pegIFN-α/RBV, and no treatment in terms of clinical outcomes, reductions in cost, and total health benefit for patients receiving treatment from both the CHC and CC disease states (Tables 4 and 5 ). Treatment with DCV þ ASV in patients with CHC who previously had a null response was associated with an increased number of QALYs per patient: 13.03, compared with 12.07, 11.05, and 10.82 when treated with TVR þ pegIFN-α/ RBV, pegIFN-α/RBV, and no treatment, respectively. Among previous partial responders and interferon-alfa-ineligible/intolerant patients, total per-patient QALYs of 13.35 and 13.43 were observed when treated with DCV þ ASV, compared with 12.58, 11.23, and 10.82 among partial responders when using TVR þ pegIFN-α/RBV, pegIFN-α/RBV, and no treatment regimens, respectively, and 10.82 among interferon-alfa-ineligible/intolerant patients who receive no treatment. Furthermore, treating patients with CC resulted in increased relative per-patient QALY gains when initiating therapy with DCV þ ASV therapy, yielding increases of up to 1.11, 2.47, and 3.05 when compared with TVR þ pegIFN-α/RBV, pegIFN-α/RBV, and no treatment, respectively. Because of the higher efficacy seen with DCV þ ASV, the lifetime risk of CC, DC, HCC, and liver-related mortality was greatly reduced in this treatment arm. Null responders incurred a reduced relative risk of 55.17% and 18.84% to 55.17% when treated with DCV þ ASV from the CHC and CC disease stage, respectively, compared with TVR þ pegIFN-α/RBV, while relative risk reductions of 63.41% and 17.01% to 63.41%, respectively, were observed in the partial responder cohort when compared with no treatment. The greatest reduction was observed among ineligible/ intolerant patients. These relative risk reductions resulted in a significantly lower cost of end-stage liver disease complication management: up to ¥1,975,431 less in null responders and ¥1,613,146 less in partial responders compared with TVR þ pegIFN-α/RBV and ¥5,273,817 less in interferon-alfa-ineligible/ Fig. 2 -Estimated cumulative incidence of end-stage liver disease complications (base-case analysis). CC, compensated cirrhosis; DC, decompensated cirrhosis; DCV þ ASV, daclatasvir þ asunaprevir; HCC, hepatocellular carcinoma; LM, liverrelated mortality; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin. CC, compensated cirrhosis; DC, decompensated cirrhosis; DCV þ ASV, daclatasvir þ asunaprevir; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; NA, not applicable; pegIFN-α/RBV, pegylated interferon-alfa þ ribavirin; SE, standard error; SVR, sustained virological response; TVR þ pegIFN-α/RBV, telaprevir þ pegylated interferon-alfa þ ribavirin.
intolerant patients compared with no treatment. Figure. 2 presents a graphical interpretation of the cumulative incidence of end-stage liver events of the lifetime of a cohort of patients treated in the CHC stage of HCV and further demonstrates the significance of the observed event reductions associated with DCV þ ASV.
Sensitivity Analysis
When using data from the global meta-analysis, similar results to the base-case analysis were observed ( 
Discussion
In modeling lifetime events associated with the use of different treatment strategies in hard-to-treat patients specific to the Japanese setting, results suggested that DCV þ ASV is superior to TVR þ pegIFN-α/RBV, pegIFN-α/RBV, and no treatment in terms of clinical outcomes, reductions in complication management costs, and total health benefit. This is reflected in increased QALY gains and reductions in end-stage liver disease complication incidence rates for DCV þ ASV over treatment regimens reflective of the current standard of care. A conclusion of the global metaanalysis was that there is a 98.1% probability that DCV þ ASV is superior to TVR þ pegIFN-α/RBV among previously treated patients [17, 18] ; therefore, the validity of the results obtained within this analysis further support the previously demonstrated claims of clinical superiority. Furthermore, it is likely that the benefit of treatment with DCV þ ASV has been underestimated because of conservative estimates of SVR used in this study. A recent phase 3 trial in Japanese patients reported SVR rates of 90.9% and 91.9% in cirrhotic and elderly patients (Z65 years), respectively [10] . There are difficulties in comparing outcome data across treatment regimens because of the lack of head-to-head trials performed in hepatitis C research. In the absence of direct comparisons, mixed-treatment and indirect comparative data can provide a useful perspective, but have inherent limitations. Because studies incorporated into the Japanese subgroup of the meta-analyses were limited and it was uncertain how well this would relate to real-world observations in clinical practice, comparisons of the outcomes observed in the broader, global meta-analysis were carried out. When using the global metaanalysis data, the sensitivity analysis produced similar results to those seen in the base case; similarly, when using individual trial data for DCV þ ASV and TVR þ pegIFN-α/RBV interferon-alfaineligible and intolerant patients, DCV þ ASV was favorable in terms of complication event rates, QALYs, and complication cost outcomes.
SVR is a clinically meaningful end point in the treatment of HCV, and a high rate of SVR observed in clinical trials of DCV þ ASV translates into a reduction in life-threatening complication rates compared with standard of care in difficult-to-treat patients. For patients treated in the CC stage, the observed incidence of HCC and resultantly liver mortality are elevated over those treated in CHC. This is due to these patients being in a more severe disease state on initiating treatment, and only these patients may still progress to HCC and liver mortality following SVR; those in CHC state do not. Lower estimates of transition to HCC in patients who have achieved SVR from the CC stage have been reported consistently [19] [20] [21] [22] ; however, in this analysis, a rate more reflective of real-world disease progression in Japan was adopted.
Tolerability, with regard to rates of rash and anemia, two significant adverse events observed with current treatment regimens, is greatly improved when using DCV þ ASV. Tolerability has an inherent effect on uptake and adherence, as well as on the quality of life in those undergoing treatment. These factors have the potential to significantly affect economic analyses and, subsequently, influence public health decisions. Furthermore, higher rates of SVR within a population could have an effect on disease transmission, an important consideration in a country with one of the highest endemic rates of infection.
Treatment options available to Japanese patients are currently limited to interferon-alfa-based regimens. Where a patient is unable to receive or has previously not responded to interferonalfa-based therapy, they do not currently have an alternative for treatment; in these patients, progression to life-threatening complications of HCV infection is likely. Conditional on the modeling assumptions applied, this study shows that the provision of an alternative, interferon-alfa-free regimen, such as DCV þ ASV, could offer valuable benefit in terms of avoiding lifethreatening liver complications and increasing patients' quality of life.
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